Palvella Therapeutics, Inc. (FRA:PI6)

Market Cap	1.02B
Revenue (ttm)	n/a
Net Income (ttm)	-27.59M
Shares Out	n/a
EPS (ttm)	-3.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	14
Open	79.50
Previous Close	80.50
Day's Range	79.50 - 79.50
52-Week Range	11.80 - 87.50
Beta	n/a
RSI	55.96
Earnings Date	Mar 31, 2026

About Palvella Therapeutics

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Way...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Wesley Kaupinen
• Employees: 14
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PI6

Financial Performance

Financial numbers in USD